MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

45.16 3.72

Overview

Share price change

24h

Current

Min

43.69

Max

45.71

Key metrics

By Trading Economics

Income

-48M

-27M

Sales

3M

99M

Profit margin

-27.41

Employees

979

EBITDA

3.2M

-21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-5.5% downside

Dividends

By Dow Jones

Next Earnings

2 Feb 2026

Market Stats

By TradingEconomics

Market Cap

669M

2.5B

Previous open

41.44

Previous close

45.16

News Sentiment

By Acuity

50%

50%

174 / 360 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

22 Jan 2026, 21:55 UTC

Earnings

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 Jan 2026, 23:52 UTC

Earnings

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 Jan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 Jan 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 Jan 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 Jan 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 Jan 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 Jan 2026, 22:37 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 Jan 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

22 Jan 2026, 21:44 UTC

Earnings

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 Jan 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 Jan 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 Jan 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 Jan 2026, 21:30 UTC

Earnings

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 Jan 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Capital One To Acquire Brex >COF

22 Jan 2026, 21:13 UTC

Earnings

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 Jan 2026, 21:11 UTC

Earnings

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 Jan 2026, 21:11 UTC

Earnings

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 Jan 2026, 21:10 UTC

Earnings

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 Jan 2026, 21:06 UTC

Earnings

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 Jan 2026, 21:05 UTC

Earnings

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 Jan 2026, 21:05 UTC

Earnings

Capital One 4Q Rev $15.58B >COF

22 Jan 2026, 21:05 UTC

Earnings

Capital One 4Q EPS $3.26 >COF

22 Jan 2026, 21:05 UTC

Earnings

Capital One 4Q Net Interest Margin 8.26% >COF

22 Jan 2026, 21:05 UTC

Earnings

Capital One 4Q Net $2.13B >COF

22 Jan 2026, 21:05 UTC

Earnings

Capital One 4Q Adj EPS $3.86 >COF

22 Jan 2026, 21:05 UTC

Earnings

Capital One 4Q Net Charge-Offs $3.8B >COF

22 Jan 2026, 21:05 UTC

Earnings

Intuitive Surgical 4Q EPS $2.21 >ISRG

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

-5.5% downside

12 Months Forecast

Average 41.25 USD  -5.5%

High 43 USD

Low 39 USD

Based on 5 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

174 / 360 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat